Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 4/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513679 | 1.00 | HPGD (0.42) | HPGDHRH1FOLH1POLBKCNH2 | |
| SCHEMBL7219340 | 0.85 | HPGD (0.41) | HPGDHRH1SMN1; SMN2CYP19A1CYP11B1 | |
| SCHEMBL5147274 | 0.82 | HPGD (0.38) | HPGDPOLBMEN1ALDH1A1KMT2A | |
| SCHEMBL5148279 | 0.82 | ALDH1A1 (0.44) | HPGDPOLBMEN1ALDH1A1KMT2A | |
| SCHEMBL6884210 | 0.80 | HPGD (0.37) | HPGDPOLBKCNH2MEN1ALDH1A1 | |
| SCHEMBL6257849 | 0.80 | HPGD (0.37) | HPGDPOLBKCNH2MEN1ALDH1A1 | |
| SCHEMBL5478147 | 0.80 | HPGD (0.50) | HPGDHRH1SMN1; SMN2 | |
| SCHEMBL795689 | 0.79 | MEN1 (0.39) | HPGDSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL6896028 | 0.79 | NCEH1 (0.41) | POLBKCNH2MEN1ALDH1A1KMT2A | |
| SCHEMBL795688 | 0.79 | MEN1 (0.39) | HPGDSMN1; SMN2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050048552-A1 | Higher order structure and binding of peptide nucleic acids | ISIS PHARMACEUTICALS, INC. | 2005-03-03 | — | — | US | disclosed |
| US-6770738-B1 | USED TO MODULATE PROTEIN ACTIVITY THROUGH, FOR EXAMPLE, TRANSCRIPTION ARREST, TRANSCRIPTION INITIATION, AND SITE SPECIFIC CLEAVAGE OF NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| EP-0776331-B1 | HIGHER ORDER STRUCTURE AND BINDING OF PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2002-11-27 | — | — | EP | disclosed |
| US-5986053-A | NUCLEIC ACID COMPLEXES WITH MULTISTRANDS AND SEQUENCES | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5641625-A | PEPTIDE NUCLEIC ACIDS FORMING DUPLEX, TRIPLEX AND OTHER STRUCTURES WITH NUCLEIC ACIDS; MODULATION OF PROTEIN ACTIVITY BY TRANSCRIPTION ARREST AND INITIATION; SPECIFIC SITE CLEAVAGE | ISIS PHARMACEUTICALS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0776331-A1 | HIGHER ORDER STRUCTURE AND BINDING OF PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1995001370-A1 | HIGHER ORDER STRUCTURE AND BINDING OF PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050048552-A1 | Higher order structure and binding of peptide nucleic acids | SSU72, DDX1, DDX18 | HPGD 4385/4885HRH1 3397/4885FOLH1 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.